Clinical Trial Update: CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS [Phase 2]

View source ↗

Summary

Phase 2 trial status update for CPX-351 in older patients with refractory or relapsed acute myeloid leukemia and myelodysplastic syndromes; the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING